HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

← Back to guidelines

Cardiology388 papers

Smoldering chronic lymphocytic leukemia

Last edited: 4/17/2026

Overview

Smoldering chronic lymphocytic leukemia (CLL) refers to a phase of CLL characterized by the presence of a high number of lymphocytes without evidence of progressive disease or symptoms requiring treatment. It is often monitored closely due to its potential to progress to active disease 4 28.

Diagnosis

Elevated lymphocyte count (typically >5000/μL) 4.

Absence of symptoms or organ dysfunction related to CLL 4.

Specific genetic markers like NOTCH1 and SF3B1 mutations may aid in risk stratification 5.

Regular monitoring including blood counts, flow cytometry, and genetic testing 4.

Management

Watchful waiting is commonly recommended for asymptomatic patients 4.

Early intervention considered for high-risk genetic mutations (e.g., TP53, ATM) 21 5.

First-line treatments include BTK inhibitors (ibrutinib, acalabrutinib, zanubrutinib) for symptomatic or high-risk smoldering CLL 1 18 31.

Combination therapies like ibrutinib with chemotherapy (bendamustine, rituximab) may be considered in relapsed/refractory cases 11 41.

Special Populations

Elderly: Tailored treatment approaches focusing on less toxic regimens like BTK inhibitors 9.

Comorbidities: Careful consideration of cardiovascular risks with BTK inhibitors due to potential atrial fibrillation and pericardial effusion 2 3 28.

Key Recommendations

Monitor high-risk genetic mutations (e.g., TP53, SF3B1) to guide early intervention 5 (Evidence: Moderate).

Initiate treatment with BTK inhibitors for symptomatic or high-risk smoldering CLL patients 1 18 (Evidence: Moderate).

Evaluate cardiovascular risk factors before prescribing BTK inhibitors due to potential arrhythmias and pericardial complications 2 3 28 (Evidence: Moderate).

References

Showing 100 most recent of 142 indexed papers.

1 Dranitsaris G, Peevyhouse A, Neuhalfen H, Dietz LA, Huynh C, Wahlstrom SK et al.. A real-world study evaluating drug tolerability and health care resource use with acalabrutinib vs ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. Journal of medical economics 2026. link 2 Hofstetter L, Shimony S, Sherban A, Raanani P, Itchaki G. Pericardial effusion and tamponade as a rare cardiac toxicity of covalent BTK inhibitors in CLL-a multi-modality study. Leukemia & lymphoma 2026. link 3 Tomasulo E, Itsara A, Haigney M, Rosing DR, Ahn IE, Peer C et al.. Sudden death and asymptomatic arrhythmia in chronic lymphocytic leukemia patients treated with ibrutinib. Heart rhythm 2026. link 4 Medina Á, Muntañola A, Crespo M, Ramírez Á, Hernández-Rivas JÁ, Abrisqueta P et al.. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia and small lymphocytic lymphoma from Chronic Lymphocytic Leukemia Spanish Group (GELLC). Medicina clinica 2025. link 5 Huang L, Shi X, Tang N, Liu J, Liang Y, Wang X. Prognostic significance of in patients with chronic lymphocytic leukemia: A meta-analysis. Annals of hematology 2025. link 6 Wen T, Sun G, Jiang W, Steiner K, Bridge S, Liu P. Comparing the efficacy and safety of first-line treatments for chronic lymphocytic leukemia: a network meta-analysis. Journal of the National Cancer Institute 2025. link 7 Simon F, Ligtvoet R, Robrecht S, Cramer P, Kutsch N, Fürstenau M et al.. End Point Surrogacy in First-Line Chronic Lymphocytic Leukemia. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2025. link 8 Cabrera-Serrano AJ, Sánchez-Maldonado JM, Rodríguez-Sevilla JJ, Reyes-Zurita FJ, Collado R, Puiggros A et al.. Identification of 4 autophagy-related genetic variants as risk factors for chronic lymphocytic leukemia. Blood advances 2025. link 9 Pula A, Robak T. Considerations for the treatment of older adults with chronic lymphocytic leukemia. Expert review of clinical pharmacology 2025. link 10 Timamopoulos C, Chatzikonstantinou T, Bonotis P, Scarfo L, Ghia P, Stamatopoulos K et al.. PEDRO: A Peer-to-Peer Support Platform for Adverse Drug Reaction Management in Patients with CLL. Studies in health technology and informatics 2025. link 11 Tan S, Choong DJ, Tan E. A systematic review of the management of eosinophilic dermatosis of hematological malignancy. International journal of dermatology 2024. link 12 Ashoub MH, Naseri A, Mohammadi P, Mohammadi M. Ofatumumab regimens in chronic lymphocytic leukemia: a meta-analysis. Annals of hematology 2023. link 13 Cabrera-Serrano AJ, Sánchez-Maldonado JM, Ter Horst R, Macauda A, García-Martín P, Benavente Y et al.. Do GWAS-Identified Risk Variants for Chronic Lymphocytic Leukemia Influence Overall Patient Survival and Disease Progression?. International journal of molecular sciences 2023. link 14 Lorenzovici L, Szilberhorn L, Farkas-Ráduly S, Gasparik AI, Precup AM, Nagy AG et al.. Systematic Literature Review of Economic Evaluations of Treatment Alternatives in Chronic Lymphocytic Leukemia. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 2023. link 15 Merli M, Ferrarini I, Merli F, Busca A, Mina R, Falini B et al.. SARS-CoV-2 infection in patients with chronic lymphocytic leukemia: The Italian Hematology Alliance on COVID-19 cohort. Hematological oncology 2023. link 16 Boriosi JP, Eickhoff JC, Bryndzia C, Peters M, Hollman GA. An exploratory study of distractions during the induction phase of pediatric procedural sedation with propofol. Paediatric anaesthesia 2023. link 17 Xia S, Ma JT, Raschi E, Ma R, Zhang BK, Guo L et al.. Tumor Lysis Syndrome with CD20 Monoclonal Antibodies for Chronic Lymphocytic Leukemia: Signals from the FDA Adverse Event Reporting System. Clinical drug investigation 2023. link 18 Hillmen P, Eichhorst B, Brown JR, Lamanna N, O'Brien SM, Tam CS et al.. Zanubrutinib Versus Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: Interim Analysis of a Randomized Phase III Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2023. link 19 . Early Clones Expand in Richter Transformation of Chronic Lymphocytic Leukemia. Cancer discovery 2022. link 20 Oerlemans S, Efficace F, Kieffer JM, Kyriakou C, Xochelli A, Levedahl K et al.. International validation of the EORTC QLQ-CLL17 questionnaire for assessment of health-related quality of life for patients with chronic lymphocytic leukaemia. British journal of haematology 2022. link 21 Baghaei Vaji F, Boroumand Nasr A, Rezvani A, Ayatollahi H, Goudarzi S, Lavasani S et al.. Prognostic significance of ATM mutations in chronic lymphocytic leukemia: A meta-analysis. Leukemia research 2021. link 22 Delestre F, Blanche P, Bouayed E, Bouscary D, Mouthon L, Brezin A et al.. Ophthalmic involvement of chronic lymphocytic leukemia: A systematic review of 123 cases. Survey of ophthalmology 2021. link 23 Jackson S, Wheatley T. Chimeric Antigen Receptor T-Cell Emergencies: Inpatient Administration, Assessment, and Management. Seminars in oncology nursing 2021. link 24 . Time-Limited Triplet Therapy Induces Rapid Undetectable MRD Responses in CLL. The oncologist 2020. link 25 Banerji V, Anglin P, Christofides A, Doucette S, Laneuville P. Updates from the American Society of Hematology 2019 annual meeting: practice-changing studies in treatment-naïve chronic lymphocytic leukemia. Current oncology (Toronto, Ont.) 2020. link 26 Islam P, Mato AR. Utilizing Real-World Evidence (RWE) to Improve Care in Chronic Lymphocytic Leukemia: Challenges and Opportunities. Current hematologic malignancy reports 2020. link 27 Kleinstern G, Rishi A, Achenbach SJ, Rabe KG, Kay NE, Shanafelt TD et al.. Delineation of clinical and biological factors associated with cutaneous squamous cell carcinoma among patients with chronic lymphocytic leukemia. Journal of the American Academy of Dermatology 2020. link 28 Stühlinger MC, Weltermann A, Staber P, Heintel D, Nösslinger T, Steurer M. Recommendations for ibrutinib treatment in patients with atrial fibrillation and/or elevated cardiovascular risk. Wiener klinische Wochenschrift 2020. link 29 Zinzani PL, Rambaldi A, Gaidano G, Girmenia C, Marchetti M, Pane F et al.. Infection control in patients treated for chronic lymphocytic leukemia with ibrutinib or idelalisib: recommendations from Italian society of hematology. Leukemia research 2019. link 30 Awan FT. Choosing ibrutinib wisely. Blood 2018. link 31 . Illuminating Aberrant mRNA Events in CLL. Cancer discovery 2018. link 32 Molica S. The future of chronic lymphocytic leukemia: potential directions from ASH 2017. Expert review of hematology 2018. link 33 Mato AR, Clasen S, Pickens P, Gashonia L, Rhodes J, Svoboda J et al.. Left atrial abnormality (LAA) as a predictor of ibrutinib-associated atrial fibrillation in patients with chronic lymphocytic leukemia. Cancer biology & therapy 2018. link 34 Brown JR. How I treat CLL patients with ibrutinib. Blood 2018. link 35 Martin P, Barr PM, James L, Pathak A, Kahl B. Long-term safety experience with bendamustine for injection in a real-world setting. Expert opinion on drug safety 2017. link 36 Shanafelt TD, Parikh SA, Noseworthy PA, Goede V, Chaffee KG, Bahlo J et al.. Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL). Leukemia & lymphoma 2017. link 37 Mozessohn L, Earle C, Spaner D, Cheng SY, Kumar M, Buckstein R. The Association of Dyslipidemia With Chronic Lymphocytic Leukemia: A Population-Based Study. Journal of the National Cancer Institute 2017. link 38 . Large Studies Expand Genomic View of CLL. Cancer discovery 2016. link 39 Nguyen-Khac F, Borie C, Callet-Bauchu E, Eclache V, Struski S. Cytogenetics in the management of chronic lymphocytic leukemia: an update by the Groupe francophone de cytogénétique hématologique (GFCH). Annales de biologie clinique 2016. link 40 Top KA, Pham-Huy A, Price V, Sung L, Tran D, Vaudry W et al.. Immunization practices in acute lymphocytic leukemia and post-hematopoietic stem cell transplant in Canadian Pediatric Hematology/Oncology centers. Human vaccines & immunotherapeutics 2016. link 41 Chanan-Khan A, Cramer P, Demirkan F, Fraser G, Silva RS, Grosicki S et al.. Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study. The Lancet. Oncology 2016. link00465-9) 42 Novacco M, Martini V, Grande C, Comazzi S. Analytic errors in Sysmex-generated hematology results in blood from a dog with chronic lymphocytic leukemia. Veterinary clinical pathology 2015. link 43 Robak T. Maintenance in CLL. Blood 2013. link 44 . Listeriosis: not only during pregnancy. Prescrire international 2013. link 45 Ghia P, Caligaris-Cappio F. Monoclonal B-cell lymphocytosis: right track or red herring?. Blood 2012. link 46 Shanafelt TD, Kay NE, Rabe KG, Inwards DJ, Zent CS, Leis JF et al.. Hematologist/oncologist disease-specific expertise and survival: lessons from chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). Cancer 2012. link 47 Pinato DJ, Rossi D, Minh MT, Toniutto P, Boccato E, Minisini R et al.. Hepatitis B virus and lymphomagenesis: novel insights into an occult relationship. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 2012. link 48 Seegers V, Chevret S, Resche-Rigon M. Dose-finding design driven by efficacy in onco-hematology phase I/II trials. Statistics in medicine 2011. link 49 Chiaretti A, Ruggiero A, Barbi E, Pierri F, Maurizi P, Fantacci C et al.. Comparison of propofol versus propofol-ketamine combination in pediatric oncologic procedures performed by non-anesthesiologists. Pediatric blood & cancer 2011. link 50 Infante PF. The IARC october 2009 evaluation of benzene carcinogenicity was incomplete and needs to be reconsidered. American journal of industrial medicine 2011. link 51 Holmes NE, Opat S, Kelman A, Korman TM. Refractory Bartonella quintana bacillary angiomatosis following chemotherapy for chronic lymphocytic leukaemia. Journal of medical microbiology 2011. link 52 Whittle AM, Allsup DJ, Bailey JR. Chronic lymphocytic leukaemia is a risk factor for venous thromboembolism. Leukemia research 2011. link 53 Panovská A, Doubek M, Brychtová Y, Mayer J. Chronic lymphocytic leukemia and focusing on epidemiology and management in everyday hematologic practice: recent data from the Czech Leukemia Study Group for Life (CELL). Clinical lymphoma, myeloma & leukemia 2010. link 54 Cantor AS, Moschos S, Jukic DM. A principal case of multiple lymphoid collision tumors involving both B-cell chronic lymphocytic leukemia and metastatic malignant melanoma. Dermatology online journal 2010. link 55 Birerdinc A, Nohelty E, Marakhonov A, Manyam G, Panov I, Coon S et al.. Pro-apoptotic and antiproliferative activity of human KCNRG, a putative tumor suppressor in 13q14 region. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 2010. link 56 Camps SM, Chevret S, Lévy V. How to use clinical vignettes in hematology--a pilot survey in the context of chronic lymphocytic leukemia. Leukemia research 2009. link 57 Hamblin TJ. Non-hemic autoimmunity in CLL. Leukemia research 2009. link 58 Mariñas EA, Vidaurrazaga N, Burgos-Bretones JJ, Eizagirre X, de Lagrán ZM, Izu R et al.. Cutaneous reactive angiomatosis associated with chronic lymphoid leukemia. The American Journal of dermatopathology 2008. link 59 Shapiro HM. Cytometry in monoclonal B-cell lymphocytosis and chronic lymphocytic leukaemia--the Hunting of the Snark?. British journal of haematology 2007. link 60 Kumagai T, Müller CI, Desmond JC, Imai Y, Heber D, Koeffler HP. Scutellaria baicalensis, a herbal medicine: anti-proliferative and apoptotic activity against acute lymphocytic leukemia, lymphoma and myeloma cell lines. Leukemia research 2007. link 61 Brugiatelli M, Bandini G, Barosi G, Lauria F, Liso V, Marchetti M et al.. Management of chronic lymphocytic leukemia: practice guidelines from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation. Haematologica 2006. link 62 Carew JS, Nawrocki ST, Krupnik YV, Dunner K, McConkey DJ, Keating MJ et al.. Targeting endoplasmic reticulum protein transport: a novel strategy to kill malignant B cells and overcome fludarabine resistance in CLL. Blood 2006. link 63 Burns CA, Scott GA, Miller CC. Leukemia cutis at the site of trauma in a patient with Burkitt leukemia. Cutis 2005. link 64 Assiri AH, Lamba M, Veinot JP. Chronic lymphocytic leukemia involving the coronary arteries with accompanying acute myocardial infarction. Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology 2005. link 65 Rollins N, Winick N, Bash R, Booth T. Acute methotrexate neurotoxicity: findings on diffusion-weighted imaging and correlation with clinical outcome. AJNR. American journal of neuroradiology 2004. link 66 Kondoh T, Morishita A, Kamei M, Okamura Y, Tamaki M, Kohmura E. Moyamoya syndrome after prophylactic cranial irradiation for acute lymphocytic leukemia. Pediatric neurosurgery 2003. link 67 Singh VP, Rai M, Shukla J, Sunder S, Usha. Chronic lymphocytic leukaemia terminating into plasma cell leukaemia. The Journal of the Association of Physicians of India 2002. link 68 Jacobs P, Wood L. Chronic lymphocytic leukaemia--the haematologic basis for diagnosis and treatment. Hematology (Amsterdam, Netherlands) 2002. link 69 Schulz H, Klein SK, Rehwald U, Reiser M, Hinke A, Knauf WU et al.. Phase 2 study of a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemia. Blood 2002. link 70 Huhn D, von Schilling C, Wilhelm M, Ho AD, Hallek M, Kuse R et al.. Rituximab therapy of patients with B-cell chronic lymphocytic leukemia. Blood 2001. link 71 Gatto-Weis C, Topolsky D, Sloane B, Hou JS, Qu H, Fyfe BS. Ulcerative balanoposthitis of the foreskin as a manifestation of chronic lymphocytic leukemia: case report and review of the literature. Urology 2000. link00735-4) 72 De Angeli C, Gandini D, Cuneo A, Moretti S, Bigoni R, Roberti MG et al.. BCL-1 rearrangements and p53 mutations in atypical chronic lymphocytic leukemia with t(11;14)(q13;q32). Haematologica 2000. link 73 Patriarca F, Gaidano G, Capello D, Zaja F, Fanin R, Baccarani M. Occurrence of multiple myeloma after fludarabine treatment of a chronic lymphocytic leukemia: evidence of a biclonal derivation and clinical response to autologous stem cell transplantation. Haematologica 2000. link 74 Quenneville LA, Magil AB. Renal failure due to T-cell mediated lymphocytic vasculitis: an unusual complication of B-cell chronic lymphocytic leukemia. American journal of kidney diseases : the official journal of the National Kidney Foundation 2000. link 75 Faderl S, Albitar M. Insights into the biologic and molecular abnormalities in adult acute lymphocytic leukemia. Hematology/oncology clinics of North America 2000. link70186-6) 76 Gorski TF, Ajemian M, Hussain E, Talhouk A, Ruskin G, Hanna A et al.. Correlation of pseudohypoxemia and leukocytosis in chronic lymphocytic leukemia. Southern medical journal 1999. link 77 Schoevaerdts D, Mineur P, Hennaux V, Sibille C. Hypercalcemia, chronic lymphocytic leukemia and multiple myeloma: uncommon association. Acta clinica Belgica 1999. link 78 Bevan S, Catovsky D, Marossy A, Matutes E, Popat S, Antonovic P et al.. Linkage analysis for ATM in familial B cell chronic lymphocytic leukaemia. Leukemia 1999. link 79 Krauss JC. Chronic lymphocytic leukemia: a brief review. Cleveland Clinic journal of medicine 1998. link 80 Pandey J, Bhowmik KT. Chronic lymphocytic leukemia presenting as jaundice. Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology 1998. link 81 Mentz F, Baudet S, Maloum K, Azgui Z, Sevin O, Vinsobre MF et al.. Quantification of apoptosis by the Abbott CD4000 hematology analyzer. Hematology and cell therapy 1998. link 82 Federman DG, Henry G. Chemotherapy-induced myocardial necrosis in a patient with chronic lymphocytic leukemia. Respiratory medicine 1997. link90092-5) 83 Sasso EH, Johnson T, Kipps TJ. Expression of the immunoglobulin VH gene 51p1 is proportional to its germline gene copy number. The Journal of clinical investigation 1996. link 84 de Fijter CW, Schuur J, Potter van Loon BJ, Kingma WP, Schweitzer MJ. Acute cardiorespiratory failure as presenting symptom of chronic lymphocytic leukemia. The Netherlands journal of medicine 1996. link00008-3) 85 Makower D, Venkatraj U, Dutcher JP, Wiernik PH. Occurrence of myeloma in a chronic lymphocytic leukemia patients after response to differentiation therapy with interleukin-4. Leukemia & lymphoma 1996. link 86 Milde P, Brunner M, Borchard F, Südhoff T, Burk M, Zumdick M et al.. Cutaneous bacillary angiomatosis in a patient with chronic lymphocytic leukemia. Archives of dermatology 1995. link 87 Porter SR, Matthews RW, Scully C. Chronic lymphocytic leukaemia with gingival and palatal deposits. Journal of clinical periodontology 1994. link 88 Zimhony O, Davidovitch Y, Shtalrid M. Chronic lymphocytic leukaemia complicated by chylothorax. Journal of internal medicine 1994. link 89 Burger H, Nooter K, Sonneveld P, Van Wingerden KE, Zaman GJ, Stoter G. High expression of the multidrug resistance-associated protein (MRP) in chronic and prolymphocytic leukaemia. British journal of haematology 1994. link 90 Juliusson G, Gahrton G. Cytogenetics in CLL and related disorders. Bailliere's clinical haematology 1993. link80178-7) 91 Foon KA, Thiruvengadam R, Saven A, Bernstein ZP, Gale RP. Genetic relatedness of lymphoid malignancies. Transformation of chronic lymphocytic leukemia as a model. Annals of internal medicine 1993. link 92 Fisch P, Forster A, Sherrington PD, Dyer MJ, Rabbitts TH. The chromosomal translocation t(X;14)(q28;q11) in T-cell pro-lymphocytic leukaemia breaks within one gene and activates another. Oncogene 1993. link 93 Wahlfors J, Hiltunen H, Heinonen K, Hämäläinen E, Alhonen L, Jänne J. Genomic hypomethylation in human chronic lymphocytic leukemia. Blood 1992. link 94 Schrek R. Intractable chronic lymphocytic leukemia and interferon. Medical hypotheses 1991. link90230-v) 95 Gabrail NY, Martin TW. Coexistence of essential thrombocythemia and chronic lymphocytic leukemia. Acta haematologica 1991. link 96 Engler HD, Troy K, Bottone EJ. Bacteremia and subcutaneous abscess caused by Proteus penneri in a neutropenic host. Journal of clinical microbiology 1990. link 97 Borche L, Lim A, Binet JL, Dighiero G. Evidence that chronic lymphocytic leukemia B lymphocytes are frequently committed to production of natural autoantibodies. Blood 1990. link 98 Sparatore A, Boido Canu C, Boido V, Sparatore F. Quinolizidine derivatives as potential antitumoral agents. Farmaco (Societa chimica italiana : 1989) 1989. link 99 Saltman DL, Ross JA, Banks RE, Ross FM, Ford AM, Mackie MJ. Molecular evidence for a single clonal origin in biphenotypic concomitant chronic lymphocytic leukemia and multiple myeloma. Blood 1989. link 100 Olson M, Posniak H. CT characteristics of a hyperdense renal mass due to Richter syndrome. Journal of computer assisted tomography 1988. link

Original source

[1]
A real-world study evaluating drug tolerability and health care resource use with acalabrutinib vs ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. — Dranitsaris G, Peevyhouse A, Neuhalfen H, Dietz LA, Huynh C, Wahlstrom SK et al. Journal of medical economics (2026)
[2]
Pericardial effusion and tamponade as a rare cardiac toxicity of covalent BTK inhibitors in CLL-a multi-modality study. — Hofstetter L, Shimony S, Sherban A, Raanani P, Itchaki G Leukemia & lymphoma (2026)
[3]
Sudden death and asymptomatic arrhythmia in chronic lymphocytic leukemia patients treated with ibrutinib. — Tomasulo E, Itsara A, Haigney M, Rosing DR, Ahn IE, Peer C et al. Heart rhythm (2026)
[4]
Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia and small lymphocytic lymphoma from Chronic Lymphocytic Leukemia Spanish Group (GELLC). — Medina Á, Muntañola A, Crespo M, Ramírez Á, Hernández-Rivas JÁ, Abrisqueta P et al. Medicina clinica (2025)
[5]
Prognostic significance of in patients with chronic lymphocytic leukemia: A meta-analysis. — Huang L, Shi X, Tang N, Liu J, Liang Y, Wang X Annals of hematology (2025)
[6]
Comparing the efficacy and safety of first-line treatments for chronic lymphocytic leukemia: a network meta-analysis. — Wen T, Sun G, Jiang W, Steiner K, Bridge S, Liu P Journal of the National Cancer Institute (2025)
[7]
End Point Surrogacy in First-Line Chronic Lymphocytic Leukemia. — Simon F, Ligtvoet R, Robrecht S, Cramer P, Kutsch N, Fürstenau M et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2025)
[8]
Identification of 4 autophagy-related genetic variants as risk factors for chronic lymphocytic leukemia. — Cabrera-Serrano AJ, Sánchez-Maldonado JM, Rodríguez-Sevilla JJ, Reyes-Zurita FJ, Collado R, Puiggros A et al. Blood advances (2025)
[9]
Considerations for the treatment of older adults with chronic lymphocytic leukemia. — Pula A, Robak T Expert review of clinical pharmacology (2025)
[10]
PEDRO: A Peer-to-Peer Support Platform for Adverse Drug Reaction Management in Patients with CLL. — Timamopoulos C, Chatzikonstantinou T, Bonotis P, Scarfo L, Ghia P, Stamatopoulos K et al. Studies in health technology and informatics (2025)
[11]
A systematic review of the management of eosinophilic dermatosis of hematological malignancy. — Tan S, Choong DJ, Tan E International journal of dermatology (2024)
[12]
Ofatumumab regimens in chronic lymphocytic leukemia: a meta-analysis. — Ashoub MH, Naseri A, Mohammadi P, Mohammadi M Annals of hematology (2023)
[13]
Do GWAS-Identified Risk Variants for Chronic Lymphocytic Leukemia Influence Overall Patient Survival and Disease Progression? — Cabrera-Serrano AJ, Sánchez-Maldonado JM, Ter Horst R, Macauda A, García-Martín P, Benavente Y et al. International journal of molecular sciences (2023)
[14]
Systematic Literature Review of Economic Evaluations of Treatment Alternatives in Chronic Lymphocytic Leukemia. — Lorenzovici L, Szilberhorn L, Farkas-Ráduly S, Gasparik AI, Precup AM, Nagy AG et al. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy (2023)
[15]
SARS-CoV-2 infection in patients with chronic lymphocytic leukemia: The Italian Hematology Alliance on COVID-19 cohort. — Merli M, Ferrarini I, Merli F, Busca A, Mina R, Falini B et al. Hematological oncology (2023)
[16]
An exploratory study of distractions during the induction phase of pediatric procedural sedation with propofol. — Boriosi JP, Eickhoff JC, Bryndzia C, Peters M, Hollman GA Paediatric anaesthesia (2023)
[17]
Tumor Lysis Syndrome with CD20 Monoclonal Antibodies for Chronic Lymphocytic Leukemia: Signals from the FDA Adverse Event Reporting System. — Xia S, Ma JT, Raschi E, Ma R, Zhang BK, Guo L et al. Clinical drug investigation (2023)
[18]
Zanubrutinib Versus Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: Interim Analysis of a Randomized Phase III Trial. — Hillmen P, Eichhorst B, Brown JR, Lamanna N, O'Brien SM, Tam CS et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
[19]
Early Clones Expand in Richter Transformation of Chronic Lymphocytic Leukemia. Cancer discovery (2022)
[20]
International validation of the EORTC QLQ-CLL17 questionnaire for assessment of health-related quality of life for patients with chronic lymphocytic leukaemia. — Oerlemans S, Efficace F, Kieffer JM, Kyriakou C, Xochelli A, Levedahl K et al. British journal of haematology (2022)
[21]
Prognostic significance of ATM mutations in chronic lymphocytic leukemia: A meta-analysis. — Baghaei Vaji F, Boroumand Nasr A, Rezvani A, Ayatollahi H, Goudarzi S, Lavasani S et al. Leukemia research (2021)
[22]
Ophthalmic involvement of chronic lymphocytic leukemia: A systematic review of 123 cases. — Delestre F, Blanche P, Bouayed E, Bouscary D, Mouthon L, Brezin A et al. Survey of ophthalmology (2021)
[23]
Chimeric Antigen Receptor T-Cell Emergencies: Inpatient Administration, Assessment, and Management. — Jackson S, Wheatley T Seminars in oncology nursing (2021)
[24]
Time-Limited Triplet Therapy Induces Rapid Undetectable MRD Responses in CLL. The oncologist (2020)
[25]
Updates from the American Society of Hematology 2019 annual meeting: practice-changing studies in treatment-naïve chronic lymphocytic leukemia. — Banerji V, Anglin P, Christofides A, Doucette S, Laneuville P Current oncology (Toronto, Ont.) (2020)
[26]
Utilizing Real-World Evidence (RWE) to Improve Care in Chronic Lymphocytic Leukemia: Challenges and Opportunities. — Islam P, Mato AR Current hematologic malignancy reports (2020)
[27]
Delineation of clinical and biological factors associated with cutaneous squamous cell carcinoma among patients with chronic lymphocytic leukemia. — Kleinstern G, Rishi A, Achenbach SJ, Rabe KG, Kay NE, Shanafelt TD et al. Journal of the American Academy of Dermatology (2020)
[28]
Recommendations for ibrutinib treatment in patients with atrial fibrillation and/or elevated cardiovascular risk. — Stühlinger MC, Weltermann A, Staber P, Heintel D, Nösslinger T, Steurer M Wiener klinische Wochenschrift (2020)
[29]
Infection control in patients treated for chronic lymphocytic leukemia with ibrutinib or idelalisib: recommendations from Italian society of hematology. — Zinzani PL, Rambaldi A, Gaidano G, Girmenia C, Marchetti M, Pane F et al. Leukemia research (2019)
[30]
Choosing ibrutinib wisely. — Awan FT Blood (2018)
[31]
Illuminating Aberrant mRNA Events in CLL. Cancer discovery (2018)
[32]
The future of chronic lymphocytic leukemia: potential directions from ASH 2017. — Molica S Expert review of hematology (2018)
[33]
Left atrial abnormality (LAA) as a predictor of ibrutinib-associated atrial fibrillation in patients with chronic lymphocytic leukemia. — Mato AR, Clasen S, Pickens P, Gashonia L, Rhodes J, Svoboda J et al. Cancer biology & therapy (2018)
[34]
How I treat CLL patients with ibrutinib. — Brown JR Blood (2018)
[35]
Long-term safety experience with bendamustine for injection in a real-world setting. — Martin P, Barr PM, James L, Pathak A, Kahl B Expert opinion on drug safety (2017)
[36]
Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL). — Shanafelt TD, Parikh SA, Noseworthy PA, Goede V, Chaffee KG, Bahlo J et al. Leukemia & lymphoma (2017)
[37]
The Association of Dyslipidemia With Chronic Lymphocytic Leukemia: A Population-Based Study. — Mozessohn L, Earle C, Spaner D, Cheng SY, Kumar M, Buckstein R Journal of the National Cancer Institute (2017)
[38]
Large Studies Expand Genomic View of CLL. Cancer discovery (2016)
[39]
Cytogenetics in the management of chronic lymphocytic leukemia: an update by the Groupe francophone de cytogénétique hématologique (GFCH). — Nguyen-Khac F, Borie C, Callet-Bauchu E, Eclache V, Struski S Annales de biologie clinique (2016)
[40]
Immunization practices in acute lymphocytic leukemia and post-hematopoietic stem cell transplant in Canadian Pediatric Hematology/Oncology centers. — Top KA, Pham-Huy A, Price V, Sung L, Tran D, Vaudry W et al. Human vaccines & immunotherapeutics (2016)
[41]
Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study. — Chanan-Khan A, Cramer P, Demirkan F, Fraser G, Silva RS, Grosicki S et al. The Lancet. Oncology (2016)
[42]
Analytic errors in Sysmex-generated hematology results in blood from a dog with chronic lymphocytic leukemia. — Novacco M, Martini V, Grande C, Comazzi S Veterinary clinical pathology (2015)
[43]
Maintenance in CLL. — Robak T Blood (2013)
[44]
Listeriosis: not only during pregnancy. Prescrire international (2013)
[45]
Monoclonal B-cell lymphocytosis: right track or red herring? — Ghia P, Caligaris-Cappio F Blood (2012)
[46]
Hematologist/oncologist disease-specific expertise and survival: lessons from chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). — Shanafelt TD, Kay NE, Rabe KG, Inwards DJ, Zent CS, Leis JF et al. Cancer (2012)
[47]
Hepatitis B virus and lymphomagenesis: novel insights into an occult relationship. — Pinato DJ, Rossi D, Minh MT, Toniutto P, Boccato E, Minisini R et al. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver (2012)
[48]
Dose-finding design driven by efficacy in onco-hematology phase I/II trials. — Seegers V, Chevret S, Resche-Rigon M Statistics in medicine (2011)
[49]
Comparison of propofol versus propofol-ketamine combination in pediatric oncologic procedures performed by non-anesthesiologists. — Chiaretti A, Ruggiero A, Barbi E, Pierri F, Maurizi P, Fantacci C et al. Pediatric blood & cancer (2011)
[50]
The IARC october 2009 evaluation of benzene carcinogenicity was incomplete and needs to be reconsidered. — Infante PF American journal of industrial medicine (2011)
[51]
Refractory Bartonella quintana bacillary angiomatosis following chemotherapy for chronic lymphocytic leukaemia. — Holmes NE, Opat S, Kelman A, Korman TM Journal of medical microbiology (2011)
[52]
Chronic lymphocytic leukaemia is a risk factor for venous thromboembolism. — Whittle AM, Allsup DJ, Bailey JR Leukemia research (2011)
[53]
Chronic lymphocytic leukemia and focusing on epidemiology and management in everyday hematologic practice: recent data from the Czech Leukemia Study Group for Life (CELL). — Panovská A, Doubek M, Brychtová Y, Mayer J Clinical lymphoma, myeloma & leukemia (2010)
[54]
A principal case of multiple lymphoid collision tumors involving both B-cell chronic lymphocytic leukemia and metastatic malignant melanoma. — Cantor AS, Moschos S, Jukic DM Dermatology online journal (2010)
[55]
Pro-apoptotic and antiproliferative activity of human KCNRG, a putative tumor suppressor in 13q14 region. — Birerdinc A, Nohelty E, Marakhonov A, Manyam G, Panov I, Coon S et al. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine (2010)
[56]
How to use clinical vignettes in hematology--a pilot survey in the context of chronic lymphocytic leukemia. — Camps SM, Chevret S, Lévy V Leukemia research (2009)
[57]
Non-hemic autoimmunity in CLL. — Hamblin TJ Leukemia research (2009)
[58]
Cutaneous reactive angiomatosis associated with chronic lymphoid leukemia. — Mariñas EA, Vidaurrazaga N, Burgos-Bretones JJ, Eizagirre X, de Lagrán ZM, Izu R et al. The American Journal of dermatopathology (2008)
[59]
Cytometry in monoclonal B-cell lymphocytosis and chronic lymphocytic leukaemia--the Hunting of the Snark? — Shapiro HM British journal of haematology (2007)
[60]
Scutellaria baicalensis, a herbal medicine: anti-proliferative and apoptotic activity against acute lymphocytic leukemia, lymphoma and myeloma cell lines. — Kumagai T, Müller CI, Desmond JC, Imai Y, Heber D, Koeffler HP Leukemia research (2007)
[61]
Management of chronic lymphocytic leukemia: practice guidelines from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation. — Brugiatelli M, Bandini G, Barosi G, Lauria F, Liso V, Marchetti M et al. Haematologica (2006)
[62]
Targeting endoplasmic reticulum protein transport: a novel strategy to kill malignant B cells and overcome fludarabine resistance in CLL. — Carew JS, Nawrocki ST, Krupnik YV, Dunner K, McConkey DJ, Keating MJ et al. Blood (2006)
[63]
Leukemia cutis at the site of trauma in a patient with Burkitt leukemia. — Burns CA, Scott GA, Miller CC Cutis (2005)
[64]
Chronic lymphocytic leukemia involving the coronary arteries with accompanying acute myocardial infarction. — Assiri AH, Lamba M, Veinot JP Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology (2005)
[65]
Acute methotrexate neurotoxicity: findings on diffusion-weighted imaging and correlation with clinical outcome. — Rollins N, Winick N, Bash R, Booth T AJNR. American journal of neuroradiology (2004)
[66]
Moyamoya syndrome after prophylactic cranial irradiation for acute lymphocytic leukemia. — Kondoh T, Morishita A, Kamei M, Okamura Y, Tamaki M, Kohmura E Pediatric neurosurgery (2003)
[67]
Chronic lymphocytic leukaemia terminating into plasma cell leukaemia. — Singh VP, Rai M, Shukla J, Sunder S, Usha The Journal of the Association of Physicians of India (2002)
[68]
Chronic lymphocytic leukaemia--the haematologic basis for diagnosis and treatment. — Jacobs P, Wood L Hematology (Amsterdam, Netherlands) (2002)
[69]
Phase 2 study of a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemia. — Schulz H, Klein SK, Rehwald U, Reiser M, Hinke A, Knauf WU et al. Blood (2002)
[70]
Rituximab therapy of patients with B-cell chronic lymphocytic leukemia. — Huhn D, von Schilling C, Wilhelm M, Ho AD, Hallek M, Kuse R et al. Blood (2001)
[71]
Ulcerative balanoposthitis of the foreskin as a manifestation of chronic lymphocytic leukemia: case report and review of the literature. — Gatto-Weis C, Topolsky D, Sloane B, Hou JS, Qu H, Fyfe BS Urology (2000)
[72]
BCL-1 rearrangements and p53 mutations in atypical chronic lymphocytic leukemia with t(11;14)(q13;q32). — De Angeli C, Gandini D, Cuneo A, Moretti S, Bigoni R, Roberti MG et al. Haematologica (2000)
[73]
Occurrence of multiple myeloma after fludarabine treatment of a chronic lymphocytic leukemia: evidence of a biclonal derivation and clinical response to autologous stem cell transplantation. — Patriarca F, Gaidano G, Capello D, Zaja F, Fanin R, Baccarani M Haematologica (2000)
[74]
Renal failure due to T-cell mediated lymphocytic vasculitis: an unusual complication of B-cell chronic lymphocytic leukemia. — Quenneville LA, Magil AB American journal of kidney diseases : the official journal of the National Kidney Foundation (2000)
[75]
Insights into the biologic and molecular abnormalities in adult acute lymphocytic leukemia. — Faderl S, Albitar M Hematology/oncology clinics of North America (2000)
[76]
Correlation of pseudohypoxemia and leukocytosis in chronic lymphocytic leukemia. — Gorski TF, Ajemian M, Hussain E, Talhouk A, Ruskin G, Hanna A et al. Southern medical journal (1999)
[77]
Hypercalcemia, chronic lymphocytic leukemia and multiple myeloma: uncommon association. — Schoevaerdts D, Mineur P, Hennaux V, Sibille C Acta clinica Belgica (1999)
[78]
Linkage analysis for ATM in familial B cell chronic lymphocytic leukaemia. — Bevan S, Catovsky D, Marossy A, Matutes E, Popat S, Antonovic P et al. Leukemia (1999)
[79]
Chronic lymphocytic leukemia: a brief review. — Krauss JC Cleveland Clinic journal of medicine (1998)
[80]
Chronic lymphocytic leukemia presenting as jaundice. — Pandey J, Bhowmik KT Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology (1998)
[81]
Quantification of apoptosis by the Abbott CD4000 hematology analyzer. — Mentz F, Baudet S, Maloum K, Azgui Z, Sevin O, Vinsobre MF et al. Hematology and cell therapy (1998)
[82]
Chemotherapy-induced myocardial necrosis in a patient with chronic lymphocytic leukemia. — Federman DG, Henry G Respiratory medicine (1997)
[83]
Expression of the immunoglobulin VH gene 51p1 is proportional to its germline gene copy number. — Sasso EH, Johnson T, Kipps TJ The Journal of clinical investigation (1996)
[84]
Acute cardiorespiratory failure as presenting symptom of chronic lymphocytic leukemia. — de Fijter CW, Schuur J, Potter van Loon BJ, Kingma WP, Schweitzer MJ The Netherlands journal of medicine (1996)
[85]
Occurrence of myeloma in a chronic lymphocytic leukemia patients after response to differentiation therapy with interleukin-4. — Makower D, Venkatraj U, Dutcher JP, Wiernik PH Leukemia & lymphoma (1996)
[86]
Cutaneous bacillary angiomatosis in a patient with chronic lymphocytic leukemia. — Milde P, Brunner M, Borchard F, Südhoff T, Burk M, Zumdick M et al. Archives of dermatology (1995)
[87]
Chronic lymphocytic leukaemia with gingival and palatal deposits. — Porter SR, Matthews RW, Scully C Journal of clinical periodontology (1994)
[88]
Chronic lymphocytic leukaemia complicated by chylothorax. — Zimhony O, Davidovitch Y, Shtalrid M Journal of internal medicine (1994)
[89]
High expression of the multidrug resistance-associated protein (MRP) in chronic and prolymphocytic leukaemia. — Burger H, Nooter K, Sonneveld P, Van Wingerden KE, Zaman GJ, Stoter G British journal of haematology (1994)
[90]
Cytogenetics in CLL and related disorders. — Juliusson G, Gahrton G Bailliere's clinical haematology (1993)
[91]
Genetic relatedness of lymphoid malignancies. Transformation of chronic lymphocytic leukemia as a model. — Foon KA, Thiruvengadam R, Saven A, Bernstein ZP, Gale RP Annals of internal medicine (1993)
[92]
The chromosomal translocation t(X;14)(q28;q11) in T-cell pro-lymphocytic leukaemia breaks within one gene and activates another. — Fisch P, Forster A, Sherrington PD, Dyer MJ, Rabbitts TH Oncogene (1993)
[93]
Genomic hypomethylation in human chronic lymphocytic leukemia. — Wahlfors J, Hiltunen H, Heinonen K, Hämäläinen E, Alhonen L, Jänne J Blood (1992)
[94]
Intractable chronic lymphocytic leukemia and interferon. — Schrek R Medical hypotheses (1991)
[95]
Coexistence of essential thrombocythemia and chronic lymphocytic leukemia. — Gabrail NY, Martin TW Acta haematologica (1991)
[96]
Bacteremia and subcutaneous abscess caused by Proteus penneri in a neutropenic host. — Engler HD, Troy K, Bottone EJ Journal of clinical microbiology (1990)
[97]
Evidence that chronic lymphocytic leukemia B lymphocytes are frequently committed to production of natural autoantibodies. — Borche L, Lim A, Binet JL, Dighiero G Blood (1990)
[98]
Quinolizidine derivatives as potential antitumoral agents. — Sparatore A, Boido Canu C, Boido V, Sparatore F Farmaco (Societa chimica italiana : 1989) (1989)
[99]
Molecular evidence for a single clonal origin in biphenotypic concomitant chronic lymphocytic leukemia and multiple myeloma. — Saltman DL, Ross JA, Banks RE, Ross FM, Ford AM, Mackie MJ Blood (1989)
[100]
CT characteristics of a hyperdense renal mass due to Richter syndrome. — Olson M, Posniak H Journal of computer assisted tomography (1988)

Share:Twitter Reddit LinkedIn